Ankyrin Repeat-Containing Protein as A Drug Target Or Biomarker

Target Name: ANKRD20A2P

NCBI ID: G441430

ANKRD20A2P

Other Name(s): Ankyrin repeat domain 20 family, member A2 | ANKRD20A2 | Putative ankyrin repeat domain-containing protein 20A2 | Ankyrin repeat domain-containing protein 20A2 pseudogene | A20A2_HUMAN | ankyrin repeat domain 20 family member A2, pseudogene | Ankyrin repeat domain-containing protein 20A2

Ankyrin Repeat-Containing Protein as A Drug Target Or Biomarker

ANKRD20A2P, also known as Ankyrin repeat domain 20 family member A2, is a protein that is expressed in various tissues throughout the body. It is a member of the A2P family, which includes proteins that contain an N-terminal ankyrin repeat and a C-terminal protein domain. The N-terminal ankyrin repeat is a characteristic feature of the A2P family, which is thought to play a role in the protein's stability and functions.

One of the unique features of ANKRD20A2P is its potential as a drug target or biomarker. The ankyrin repeat is a highly conserved region that is found in a variety of proteins, including many that are involved in signaling pathways. As such, ANKRD20A2P is a potential target for small molecules that can modulate its activity and influence the functions of cells.

In addition to its potential as a drug target, ANKRD20A2P is also a potential biomarker for a variety of diseases. For example, it has been shown to be expressed in various tissues and cells that are involved in the development and progression of cancer, including breast, ovarian, and prostate cancer. As such, ANKRD20A2P may be a useful biomarker for these diseases and could potentially be used in the development of new treatments.

The ankyrin repeat is a conserved region that is found in many proteins, including ANKRD20A2P. It is characterized by a repeated sequence of amino acids that is usually composed of four amino acids (such as Asp or Glu) that are arranged in a specific sequence. The N-terminal ankyrin repeat is the most well-studied of the A2P family and is thought to play a role in the protein's stability and functions.

The N-terminal ankyrin repeat is also thought to be involved in the regulation of various cellular processes, including cell signaling, DNA replication, and metabolism. It is also involved in the formation of inclusion bodies, which are structures that can interact with and modulate the activity of other proteins.

In addition to its role in cellular processes, the N-terminal ankyrin repeat is also thought to play a role in the development and progression of diseases. For example, it has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. It is also thought to be involved in the development of certain cancers, including breast, ovarian, and prostate cancer.

The potential drug targeting of ANKRD20A2P is based on its conserved N-terminal ankyrin repeat and its involvement in various cellular processes. Small molecules that can modulate the activity of this protein and its functions may be developed as potential drugs for the treatment of various diseases.

In conclusion, ANKRD20A2P is a protein that is expressed in various tissues throughout the body and is thought to play a role in the regulation of various cellular processes. Its potential as a drug target or biomarker for various diseases makes it an attractive target for research and development of new treatments. Further studies are needed to fully understand the role of ANKRD20A2P in cellular processes and its potential as a drug target or biomarker.

Protein Name: Ankyrin Repeat Domain 20 Family Member A2, Pseudogene

The "ANKRD20A2P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ANKRD20A2P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets